Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
The Best Food Scene You Don’t Know About Is in Buffalo, New York
By Adam Reiner, Bloomberg News Buffalo might be synonymous with hot wings, but there’s a less heralded bar staple that...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Your Brain’s Secret Defense Against Alzheimer’s
By Brendon Fallon and Lynn Xu For many people, Alzheimer’s disease casts an increasingly large shadow as mental fog, forgotten...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...
Rivian Recalls Nearly 35,000 Delivery Vans Over Seat Belt Misuse Issue
By Rob Sabo Electric vehicle (EV) manufacturer Rivian Automotive announced on Dec. 3 it is recalling 34,824 delivery vans due...